Key Points
- Alphatec EVP David Sponsel sold 60,425 shares on Feb. 5 at an average price of $13.79, generating $833,260.75 and reducing his direct stake by 14.74% to 349,500 shares (valued ≈ $4.82M).
- Sponsel also sold 21,106 shares on Dec. 10 at $20.79 and 988 shares on Dec. 8 at $21.45, signaling continued insider selling over recent months.
- ATEC opened at $13.82 with a 12‑month range of $8.81–$23.29 and a $2.05B market cap, while analysts carry a consensus "Moderate Buy" rating and a consensus target of $22.82 (individual targets up to $27).
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP David Sponsel sold 60,425 shares of the stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $13.79, for a total value of $833,260.75. Following the completion of the sale, the executive vice president directly owned 349,500 shares of the company's stock, valued at approximately $4,819,605. This represents a 14.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
David Sponsel also recently made the following trade(s):
- On Wednesday, December 10th, David Sponsel sold 21,106 shares of Alphatec stock. The stock was sold at an average price of $20.79, for a total value of $438,793.74.
- On Monday, December 8th, David Sponsel sold 988 shares of Alphatec stock. The stock was sold at an average price of $21.45, for a total transaction of $21,192.60.
Alphatec Stock Up 2.4%
Shares of ATEC stock opened at $13.82 on Friday. Alphatec Holdings, Inc. has a twelve month low of $8.81 and a twelve month high of $23.29. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. The stock's 50 day simple moving average is $18.85 and its 200 day simple moving average is $17.01. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -13.29 and a beta of 1.01.
Hedge Funds Weigh In On Alphatec
Several large investors have recently modified their holdings of the stock. Creative Planning grew its position in shares of Alphatec by 0.9% in the third quarter. Creative Planning now owns 58,654 shares of the medical technology company's stock valued at $853,000 after purchasing an additional 534 shares during the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Alphatec by 2.1% during the 3rd quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company's stock valued at $600,000 after acquiring an additional 846 shares during the period. Norden Group LLC lifted its position in Alphatec by 2.6% during the third quarter. Norden Group LLC now owns 36,676 shares of the medical technology company's stock worth $533,000 after purchasing an additional 939 shares during the period. Arizona State Retirement System lifted its holdings in shares of Alphatec by 2.8% during the 3rd quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company's stock worth $503,000 after acquiring an additional 949 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its stake in Alphatec by 8.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company's stock worth $131,000 after purchasing an additional 955 shares during the last quarter. 66.35% of the stock is owned by institutional investors.
Analysts Set New Price Targets
ATEC has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, January 31st. TD Cowen restated a "buy" rating on shares of Alphatec in a research report on Tuesday, January 27th. HC Wainwright reaffirmed a "buy" rating and set a $24.00 price objective on shares of Alphatec in a research note on Monday, January 12th. Barclays upped their target price on shares of Alphatec from $23.00 to $27.00 and gave the company an "overweight" rating in a research note on Wednesday, January 7th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $25.00 price target (up previously from $20.00) on shares of Alphatec in a research report on Friday, October 31st. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Alphatec currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.82.
Get Our Latest Stock Report on ATEC
Alphatec Company Profile
(
Get Free Report)
Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.
Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
